Antiarrhythmic therapy in patients with congestive heart failure

References

• Francis GS. Development of arrhythmias in the patient with congestive heart failure: pathophysiology, prevalence and prognosis. Am J Cardiol 1986; 57(3): 3–7B
   PubMed Web of Science ®Google Scholar
• Singh SN, Bennett BH. Ventricular arrhythmias associated with congestive heart failure: the role for amiodarone. J Clin Pharmacol 1991; 31(11): 1109–11
   PubMed Web of Science ®Google Scholar
• Chakko CS, Gheorghiade M. Ventricular arrhythmias in severe heart failure: incidence, significance, and effectiveness of antiarrhythmic therapy. Am Heart J 1985; 109 (3 Pt 1): 497–504
   PubMed Web of Science ®Google Scholar
• Parmley WW. Pathophysiology and current therapy of congestive heart failure. J Am Coll Cardiol 1989; 13(4): 771–85
   PubMed Web of Science ®Google Scholar
• Mukharji J, Rude RE, Poole WK, et al. Risk factors for sudden death after acute myocardial infarction: two-year follow-up. Am J Cardiol 1984; 54(1): 31–6
   PubMed Web of Science ®Google Scholar
• Bigger JT Jr, Heiss JL, Kleiger R, et al. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 1984; 69(2): 250–8
   PubMed Web of Science ®Google Scholar
• Gradman A, Deedwania P, Cody R, et al. Predictors of total mortality and sudden death in mild to moderate heart failure. J Am Coll Cardiol 1989;14(3): 564–70
   PubMed Web of Science ®Google Scholar
• The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321 (6): 406–12
   PubMed Web of Science ®Google Scholar
• The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327(4): 227–33
   PubMed Web of Science ®Google Scholar
• Burkart F, Pfisterer M, Kiowski W, et al. Improved survival of patients with asymptomatic ventricular arrhythmias after myocardial infarction with amiodarone: controlled trial. (Abstr) Circulation 1989; 80(Suppl IV): II119
   Google Scholar
• Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, et al. Effect of amiodarone on mortality after myocardial infarction: a doubleblind, placebo-controlled, pilot study. J Am Coll Cardiol 1992;20(5): 1056–62
   PubMed Web of Science ®Google Scholar
• Singh SN, Bennett BH. Ventricular arrhythmias associated with congestive heart failure: the role for amiodarone. J Clin Pharmacol 1991; 31(11): 1109–11
   PubMed Web of Science ®Google Scholar
• Marchlinski FE, Buxton AE, Waxman HL, et al. Identifying patients at risk of sudden death after myocardial infarction: value of the response to programmed stimulation, degree of ventricular ectopic activity and severity of left ventricular dysfunction. Am J Cardiol 1983; 52(10): 1190–6
   PubMed Web of Science ®Google Scholar
• Buxton AE, Marchlinski FE, Flores BT, et al. Nonsustained ventricular tachycardia in patients with coronary artery disease: role of electrophysiologic study. Circulation 1987; 75(6):1178–85
   PubMed Web of Science ®Google Scholar
• Gomes JA, Winters SL, Stewart D, et al. A new noninvasive index to predict sustained ventricular tachycardia and sudden death in the first year after myocardial infarction: based on signal-averaged electrocardiogram, radionuclide ejection fraction and Holter monitoring. J Am Coll Cardiol 1987; 10(2): 349–57
   PubMed Web of Science ®Google Scholar
• von Olshausen K, Schafer A, Mehmel HC, et al. Ventricular arrhythmias in idiopathic dilated cardiomyopathy. Br Heart J 1984; 51(2): 195–201
   PubMedGoogle Scholar
• Pbdrid PJ, Fuchs TT. Left ventricular dysfunction and ventricular arrhythmias: reducing the risk of sudden death. J Clin Pharmacol 1991; 31(11): 1096–104
   PubMed Web of Science ®Google Scholar
• Hofmann T, Meinertz T, Kasper W et al. Mode of death in idiopathic dilated cardiomyopathy: a multivariate analysis of prognostic determinants. Am Heart J 1988; 116(6 Pt 1): 1455–63
   PubMed Web of Science ®Google Scholar
• Meinertz T, Hofmann T, Kasper W, et al. Significance of ventricular arrhythmias in idiopathic dilated cardiomyopathy. Am J Cardiol 1984; 53(7): 902–7
   PubMed Web of Science ®Google Scholar
• Unverferth DV, Magorien RD, Moeschberger ML, et al. Factors influencing the one-year mortality of dilated cardiomyopathy. Am J Cardiol 1984;54(1): 147–52
   PubMed Web of Science ®Google Scholar
• Olshausen KV, Stienen U, Schwarz F, et al. Long-term prognostic significance of ventricular arrhythmias in idiopathic dilated cardiomyopathy. Am J Cardiol 1988; 61(1): 146–51
   PubMed Web of Science ®Google Scholar
• Gottlieb SS, Kukin ML, Yushak M, et al. Adverse hemodynamic and clinical effects of en-cainide in severe chronic heart failure. Ann Intern Med 1989; 110(7): 505–9
   PubMed Web of Science ®Google Scholar
• Gottlieb SS, Kukin ML, Medina N, et al. Comparative hemodynamic effects of procainamide, tocainide, and encainide in severe chronic heart failure. Circulation 1990; 81: 860–4
   PubMed Web of Science ®Google Scholar
• Gottlieb SS, Weinberg M. Comparative hemodynamic effects of mexiletine and quinidine in patients with severe left ventricular dysfunction. Am Heart J 1991; 122(5): 1368–74
   PubMed Web of Science ®Google Scholar
• Nicklas JM, McKenna TKJ, Stewart RA, et al. Prospective, double-blind, placebo-controlled trial of low-dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy. Am Heart J 1991; 122(4 Pt 1): 1016–21
   PubMed Web of Science ®Google Scholar
• Hamer AW, Arkles LB, Johns JA. Beneficial effects of low dose amiodarone in patients with congestive cardiac failure: a placebo-controlled trial. J Am Coll Cardiol 1989; 14(7): 1768–74
   PubMed Web of Science ®Google Scholar
• Cleland JG, Dargie HJ, Findlay IN, et al. Clinical, haemodynamic, and antiarrhythmic effects of long term treatment with amiodarone of patients in heart failure. Br Heart J 1987; 57(5): 436–45
   PubMedGoogle Scholar
• Neri R, Mestroni L, Salvi A, et al. Ventricular arrhythmias in dilated cardiomyopathy: efficacy of amiodarone. Am Heart J 1987; 113(3): 707–15
   PubMed Web of Science ®Google Scholar
• Meinertz T, Treese N, Kasper W, et al. Determinants of prognosis in idiopathic dilated cardiomyopathy as determined by programmed electrical stimulation. Am J Cardiol 1985;56(4): 337–41
   PubMed Web of Science ®Google Scholar
• Das SK, Morady F, DiCarlo L Jr, et al. Prognostic usefulness of programmed ventricular stimulation in idiopathic dilated cardiomyopathy without symptomatic ventricular arrhythmias. Am J Cardiol 1986; 58(10): 998–1000
   PubMed Web of Science ®Google Scholar
• Brodsky MA, Allen BJ, Baron D, et al. Enhanced survival in patients with heart failure and life-threatening ventricular tachyarrhythmias. Am Heart J 1986; 112(6): 1166–72
   PubMed Web of Science ®Google Scholar
• Josephson ME. Clinical cardiac electro- physiology: techniques and interpretations. 2d ed. Philadelphia: Lea & Febiger, 1989: 446
   Google Scholar
• Mason JW, Winkle RA. Accuracy of the ventricular tachycardia-induction study for predicting long-term efficacy and inefficacy of antiarrhythmic drugs. N Engl J Med 1980; 303(19): 1073–7
   PubMed Web of Science ®Google Scholar
• Kim SG. The management of patients with life-threatening ventricular tachyarrhythmias: programmed stimulation or Holter monitoring (either or both)? Circulation 1987;76(1): 1–5
   PubMed Web of Science ®Google Scholar
• Mitchell LB, Duff HJ, Manyari DE, et al. A randomized clinical trial of the noninvasive and invasive approaches to drug therapy of ventricular tachycardia. N Engl J Med 1987; 317(27): 1681–7
   PubMed Web of Science ®Google Scholar
• The ESVEM Investigators. The ESVEM trial: Electrophysiologic Study Versus Electrocardiographic Monitoring for Selection of Antiarrhythmic Therapy of Ventricular Tachyarrhythmias. Circulation 1989;79(6): 1354–60
   PubMed Web of Science ®Google Scholar
• The ESVEM Investigators. Determinants of predicted efficacy of antiarrhythmic drugs in the electrophysiologic study versus electrocardiographic monitoring trial. Circulation 1993; 87(2): 323–9
   PubMed Web of Science ®Google Scholar
• Brembilla-Ptrrot B, Donetti J, de la Chaise AT, et al. Diagnostic value of ventricular stimulation in patients with idiopathic dilated cardiomyopathy. Am Heart J 1991;121(4 Pt 1): 1124–31
   PubMed Web of Science ®Google Scholar
• Poll DS, Marchlinski FE, Buxton AE, et al. Usefulness of programmed stimulation in idiopathic dilated cardiomyopathy. Am J Cardiol 1986; 58(10): 992–7
   PubMed Web of Science ®Google Scholar
• Rae AP, Spielman SR, Kutalek SP, et al. Electrophysiologic assessment of antiarrhythmic drag efficacy for ventricular tachyarrhythmias associated with dilated cardiomyopathy. Am J Cardiol 1987; 59(4): 291–5
   PubMed Web of Science ®Google Scholar
• Pratt CM, Eaton T, Francis M, et al. The inverse relationship between baseline left ventricular ejection fraction and outcome of anti-arrhythmic therapy: a dangerous imbalance in the risk-benefit ratio. Am Heart J 1989; 118(3): 433–40
   PubMed Web of Science ®Google Scholar
• Slater W, Lampert S, Podrid PJ, et al. Clinical predictors of arrhythmia worsening by antiarrhythmic drugs. Am J Cardiol 1988; 61(4): 349–53
   PubMed Web of Science ®Google Scholar